Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed Mahmood, Michael G. Fradley, Justine Vanessa Cohen et al. · Journal of the American College of Cardiology · 2018
Cited by 1,588 works. doi:10.1016/j.jacc.2018.02.037 Open-access PDF
Authors
- Syed Mahmood
- Michael G. Fradley
- Justine Vanessa Cohen
- Anju Nohria
- Kerry Lynn Reynolds
- Lucie Heinzerling
- Ryan Joseph Sullivan
- Rongras Damrongwatanasuk
- Carol L. Chen
- Dipti Gupta
- Michael Constantin Kirchberger
- Magid Awadalla
- Malek Z. O. Hassan
- Javid J. Moslehi
- Sachin P. Shah
- Sarju Ganatra
- Paaladinesh Thavendiranathan
- Donald P. Lawrence
- John D. Groarke
- Tomas G. Neilan
References
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
- Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- 2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities
- The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy